Hormones and prostate cancer: current perspectives and future directions (Q34732880)

4 August 2017

1 reference

title

Hormones and prostate cancer: current perspectives and future directions (English)

1 reference

4 August 2017

1 reference

2

Juergen K V Reichardt

1 reference

4 August 2017

3

Frank Z Stanczyk

1 reference

4 August 2017

Ann W Hsing

1

1 reference

4 August 2017

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

52

1 reference

4 August 2017

3

1 reference

4 August 2017

213-235

1 reference

International trends and patterns of prostate cancer incidence and mortality

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Trends and patterns of prostate cancer: what do they suggest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Anti-androgens and other hormonal therapies for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Hormones and prostate cancer: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Molecular genetics of steroid 5 alpha-reductase 2 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Peripheral androgens and the role of androstanediol glucuronide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Molecular action of androgen in the normal and neoplastic prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Regulation of prostatic growth and function by peptide growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Role of the insulin-like growth factor family in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Insulin-like growth factors and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Estrogen in the etiopathogenesis of BPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

The role of estrogen receptor, androgen receptor and growth factors in diethylstilbestrol-induced programming of prostate differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Cancer risk in men exposed in utero to diethylstilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

An update on estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Androgen, estrogen, and progesterone receptors in normal and aging prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

A role for estrogen receptor beta in the regulation of growth of the ventral prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Sex hormone-binding globulin: not only a transport protein. What news is around the corner?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Roles of estrogen and SHBG in prostate physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Body size and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Leptin in relation to prostate cancer and benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Prostate cancer risk and serum levels of insulin and leptin: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Leptin and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Role of cytochrome P450c17 in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Insulin alters the effects of follicle stimulating hormone on aromatase in bovine granulosa cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Multiple signaling pathways involved in the metabolic effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Insulin and IGF-I receptors signaling in protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Insulin and insulin-like growth factor-I receptor mediated differentiation of 3T3-F442A cells into adipocytes: effect of PI 3-kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Plasma prolactin and prostate cancer risk: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Interaction of prolactin and testosterone in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

A polymorphism in the CYP17 gene is associated with prostate cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Clinical and Biochemical Parameters of Androgen Action in Normal Healthy CaucasianVersusChinese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Linkage of prostate cancer susceptibility loci to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Polymorphism of the androgen receptor gene is associated with male pattern baldness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Amplified in Breast Cancer-1 Glutamine Repeat and Prostate Cancer Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Determination of dehydroepiandrosterone sulphate in biological samples by liquid chromatography/atmospheric pressure chemical ionization-mass spectrometry using [7,7,16,16-2H4]-dehydroepiandrosterone sulphate as an internal standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

21 January 2018

Familial prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Genetics of prostate cancer: too many loci, too few genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

Gene-environment interrelations in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

(CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10108

21 January 2018

Identifiers

DOI

10.1002/PROS.10108

1 reference

4 August 2017

1 reference

PubMed ID

12111697